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Abstract We investigated the contractile roles of M2 and
M 3 muscarinic receptors in urinary bladder from
streptozotocin-treated mice. Wild-type and M2 muscarinic
receptor knockout (M2 KO) mice were given a single
injection of vehicle or streptozotocin (125 mg kg−1) 2–
24 weeks prior to bladder assays. The effect of forskolin on
contractions elicited to the muscarinic agonist,
oxotremorine-M, was measured in isolated urinary bladder
(intact or denuded of urothelium). Denuded urinary bladder
from vehicle-treated wild-type and M2 KO mice exhibited
similar contractile responses to oxotremorine-M, when
contraction was normalized relative to that elicited by KCl
(50 mM). Eight to 9 weeks after streptozotocin treatment,
the EC50 value of oxotremorine-M increased 3.1-fold in
urinary bladder from the M2 KO mouse (N=5) compared to
wild type (N=6; P<0.001). Analogous changes were
observed in intact bladder. In denuded urinary bladder from
vehicle-treated mice, forskolin (5 µM) caused a much
greater inhibition of contraction in M 2 KO bladder
compared to wild type. Following streptozotocin treatment,
this forskolin effect increased 1.6-fold (P=0.032). At the
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20- to 24-week time point, the forskolin effect increased
1.7-fold for denuded as well as intact bladders (P=0.036,
0.01, respectively). Although streptozotocin treatment
inhibits M3 receptor-mediated contraction in denuded
urinary bladder, muscarinic contractile function is maintained in wild-type bladder by enhanced M2 contractile
function. M2 receptor activation opposes forskolin-induced
relaxation of the urinary bladder, and this M2 function is
enhanced following streptozotocin treatment.
Keywords M2 muscarinic receptor . Urinary bladder .
Contraction . Streptozotocin . Diabetes . Smooth muscle

Introduction
Diabetes is associated with an alteration in the contractility of
urinary bladder smooth muscle in addition to the well-known
increase in urinary frequency (Longhurst and Belis 1986;
Latifpour et al. 1989; Michel and Barendrecht 2008). The
two main neurotransmitters eliciting contraction in human
and rodent urinary bladder are adenosine triphosphate and
acetylcholine, which act on a ligand-gated ion channel (P2X
receptor) and two G-protein-coupled receptors (M2 and M3
muscarinic), respectively (de Groat and Yoshimura 2001). A
common approach for studying how the functions of these
receptors change in diabetes mellitus is to examine their
contractile roles in isolated urinary bladder from animals
treated with streptozotocin (STZ).
Treatment with STZ causes a hypertrophy of the rat
urinary bladder (Longhurst and Belis 1986; Latifpour et al.
1989) and an upregulation in M2 and M3 muscarinic
receptors in the urothelium and smooth muscle (Tong and
Cheng 2002; Tong et al. 2006; Cheng et al. 2007). Not
surprisingly, the contractile response to muscarinic agonists
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in whole urinary bladder increases following STZ
treatment (Kolta et al. 1985; Nsabimana and Ojewole
2008). To control for the STZ-induced hypertrophy,
several investigators have normalized contraction relative
to the cross-sectional area of the muscle strip or have
measured contractions in strips of urinary bladder having a
similar cross-sectional area. These studies have yielded
conflicting reports, however, including an increase
(Latifpour et al. 1989), a decrease (Longhurst and Belis
1986), and no change (Lincoln et al. 1984) in muscarinic
agonist-induced contraction. Whether there are specific
changes in the contractile functions of M2 and M3
muscarinic receptors in urinary bladder from STZ-treated
rodents is unknown.
In smooth muscle from the urinary bladder and several
other organs, the M2 receptor outnumbers the M3 by a ratio
that is often at least four to one, yet its function at the level
of contraction is less than obvious (Ehlert 2003a, b). For
example, it has long been known that subtype-selective
muscarinic antagonists inhibit contraction of the urinary
bladder with a profile consistent with that of an M3
mechanism (Hegde and Eglen 1999). In addition, there is
little loss of muscarinic agonist-induced contraction in
isolated urinary bladder from the M2 muscarinic receptor
knockout out (M2 KO) mouse (Matsui et al. 2000, 2002). In
smooth muscle from the M3 KO mouse, muscarinic
agonists elicit contraction, and this response is lost in the
M2/M3 double KO mouse, indicating that the M2 receptor
can mediate contraction. Although the potency of this
response is high, its Emax expressed relative to that of wild
type is only 10% in urinary bladder and about 30% in ileum
and the fundus of the stomach (Matsui et al. 2000; Stengel
et al. 2002). Thus, experiments on the M3 KO mouse have
revealed a small role for the M2 receptor in contraction. In
guinea pig ileum, this high-potency M2 mechanism is
absent (Griffin et al. 2009).
Part of the reason why the M2 receptor appears to have
little role in the experiments described above can be
explained by the nature of some of the Gi-signaling
pathways of the M2 receptor in smooth muscle. Muscarinic
activation of smooth muscle elicits a Ca2+-dependent
nonselective cation conductance (Icat; Bolton 1979; Inoue
1991). This conductance is pertussis toxin-sensitive (Inoue
and Isenberg 1990), and it is greatly inhibited in intestinal
smooth muscle from either the M2 KO or the M3 KO
mouse (Sakamoto et al. 2007). Muscarinic receptor
activation indirectly stimulates a Ca 2+ -activated K +
(BKCa) channel in smooth muscle from guinea pig trachea
(Wade and Sims 1993) and many other organs, presumably through mobilization of Ca2+ by the M3 receptor.
This conductance may represent an inhibitory-feedback
mechanism to suppress excessive excitation of smooth
muscle. Muscarinic receptor activation in canine colon
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(Cole and Sanders 1989) and many other types of smooth
muscle also directly inhibits the BKCa channel, and this
response is pertussis toxin-sensitive (Kume et al. 1995;
Nakamura et al. 2002), which suggests a role for the M2
receptor. In rat urinary bladder, pertussis toxin-treatment
and M2 selective antagonists inhibit the direct muscarinic
suppression of BKCa (Nakamura et al. 2002). Both the M2
inhibition of the BKCa channel and the M2 stimulation of
Icat are expected to be lost in the M3 KO mouse, because
they are contingent upon Ca2+ mobilization triggered by
M3 receptor activation. Perhaps this accounts for the near
complete loss of muscarinic contractile function in urinary
bladder from the M3 KO mouse. Obviously, this M2–M3
interaction mechanism cannot account for the residual M2
receptor-mediated contraction in the ileum and fundus of
the stomach from the M3 KO mouse.
One might expect some decrease in muscarinic agonistinduced contraction in smooth muscle from the M2 KO
mouse or from pertussis toxin-treated animals because of
the loss of M2 conductance mechanisms just described. In
most instances, however, this is not observed (Thomas and
Ehlert 1994; Sawyer and Ehlert 1999; Ehlert 2003a). We
have previously shown that the potency of the M2
enhancement mechanism in intestinal (Sawyer and Ehlert
1999; Ehlert 2003a) and urinary bladder (Ehlert et al. 2005,
2007) smooth muscle is less than that of the M3 contractile
mechanism so that muscarinic contractions are already
maximal at an agonist concentration that is too low to
trigger M2 mechanisms. One exception is the mouse uterus
where muscarinic agonist-induced contraction is greatly
inhibited in the M2 KO mouse (Kitazawa et al. 2008).
In smooth muscle, cAMP mediates relaxation, and
activation of the M2 receptor inhibits adenylate cyclase
and the relaxation elicited by forskolin and activation of
β-adrenoceptors in gastrointestinal and urinary bladder
smooth muscle (Ehlert 2003b). The potency of muscarinic
agonists for eliciting this response in the guinea pig ileum is
actually greater than that for eliciting a direct contraction
through the M3 receptor (Ostrom and Ehlert 1997). In bovine
and guinea pig trachea, M2 receptor activation inhibits
forskolin- but not isoproterenol-mediated relaxation, suggesting that the β-adrenoceptor mediates relaxation through a
non-cAMP mechanism (Ostrom and Ehlert 1998).
The M3 receptor interacts with Gq to mediate phosphoinositide hydrolysis and direct contraction in smooth muscle
(Ehlert 2003b). Both the effect on phosphoinositide
hydrolysis and contraction are pertussis toxin-insensitive
(Ehlert 2003b). While many Gq-linked receptors elicit
contraction in smooth muscle, the source of Ca2+ for M3
receptor-mediated contractions is mainly extracellular
through voltage-sensitive Ca2+ channels (Bolger et al.
1983). How the M3 receptor triggers an influx of Ca2+ is
unclear. Most of the older electrophysiological literature
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suggests that the initial depolarization occurs through Icat
followed by an influx of Ca2+ through voltage-sensitive
channels, but neither the activation of Icat nor the inhibition
of BKCa channels can explain the potent muscarinic
agonist-induced contraction of isolated smooth muscle
because the latter is insensitive to pertussis toxin (Ehlert
2003b), whereas the former two ionic mechanisms are
pertussis toxin-sensitive (see above).
Given the importance of the STZ model of diabetes, we
undertook a study to determine how M2 and M3 receptormediated contractions are altered in isolated urinary bladder
from STZ-treated mice. We observed an increase in M2 and
a decrease in M3 receptor-mediated contractions in urinary
bladder smooth muscle from STZ-treated mice. We also
observed a similar phenomenon in urinary bladder with
intact urothelium, although the results are more complicated
because of changes in muscarinic function in the urothelium
with STZ treatment.

Methods
Animals
All procedures were approved by the Institutional Laboratory
Animal Care and Use Committee. M2 muscarinic receptor
knockout (M2 KO) mice were generated as previously
described (Matsui et al. 2000, 2002). Male C57BL/6 wildtype (Harlan Sprague Dawley, Inc., Indianapolis, IN, USA)
and M2 KO mice (2–3 months old, 18–30 g) were fasted for
4–6 h and then briefly anesthetized with isoflurane (Phoenix
Pharmaceuticals, Inc., St. Joseph, MO, USA) before a single
intraperitoneal injection with either vehicle (sodium citrate
dihydrate, Fisher Scientific, Pittsburgh, PA, USA) or
125 mg kg−1 of STZ (Sigma Aldrich Chemical, St. Louis,
MO, USA) 2 to 24 weeks prior to experiments on isolated
bladder. Water containing 10% sucrose was given to
animals 48 h after injection to prevent hypoglycemic
shock. All mice were housed in a 12-h light/dark facility
with free access to water and food. Blood glucose was
measured using an Ascensia Contour glucometer (Bayer,
Leverkusen, Germany), and diabetic ketoacidosis was
assessed by Keto-Diastix (Bayer, Leverkusen, Germany).
Heparinized saline was used to dilute and estimate blood
glucose levels above the 600-mg/dL glucometer limit.
Isolated urinary bladder
Whole mouse urinary bladder was removed and cut in half
sagittally. The urothelium was carefully dissected from one
of the strips, while the other was left intact. Half-bladder
strips were mounted in an organ bath in a longitudinal
orientation and connected to a force-displacement trans-
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ducer using silk thread. Tissues were immersed in a Krebs–
Ringer bicarbonate buffer (124 mM NaCl, 5 mM KCl,
1.3 mM MgSO4, 26 mM NaHCO3, 1.2 mM KH2PO4,
1.8 mM CaCl2, and 10 mM glucose) at 37°C and gassed
with O2/CO2 (19:1) as previously described (Ehlert et al.
2005). Resting tension was adjusted to a load of 1 g
(9.8 mN) during an equilibration period of at least 1 h.
Contractile responses were first generated by two test doses
of KCl (50 mM). Bladder was washed and allowed to rest
for 10 min after each test dose. The contractile response to
KCl was calculated as the stable plateau value after a 3-min
period minus the initial resting tension. Responses to other
agents were either expressed in millinewton of force or
normalized relative to the larger of the two responses to
KCl, which were usually similar.
Contraction of the urinary bladder to the highly
efficacious muscarinic agonist, oxotremorine-M, was measured using a cumulative technique. Each aliquot of the
agonist was added to the bath, and the response was
calculated as the stable plateau achieved within approximately 1 min minus the initial resting tension. Figure 1
shows a representative recording with the arrows indicating
the final cumulative concentrations of agonist. After a
complete concentration–response curve was measured,
tissues were washed five to eight times over a period of
35–45 min before measurement of another curve. This
initial concentration–response curve was not utilized but
enabled the bladder to equilibrate and to achieve a maximal
contractile state. Subsequent responses were recorded in a
similar manner and are described under “Results” section.
Analysis of oxotremorine-M concentration–response curves
The maximal response (Emax) and concentration of agonist
eliciting half-maximal response (EC50) were estimated from
the concentration–response curve using nonlinear regression

Fig. 1 Contractile response of denuded urinary bladder to
oxotremorine-M measured using a cumulative technique. The urinary
bladder was from a wild-type mouse that had been treated with
streptozotocin approximately 20 weeks prior. Force of contraction of
this representative experiment is plotted against time. The arrows
indicate when aliquots of oxotremorine-M were added to the tissue
bath. The final, cumulative concentration of oxotremorine-M is
indicated beneath each arrow
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analysis with Prism software (GraphPad Software, Inc.,
Diego, CA, USA).
To estimate the potential loss of function in the M2
mouse bladder relative to wild type, we fitted
concentration–response curves from wild-type and M2
mice to Eqs. 1 and 2, respectively:
y¼

y¼

X n Emax
X n þ EC50 n
X n ðEmax þ dÞ
X n þ gEC50 n

San
KO
the
KO

ð1Þ

ð2Þ

In both of these equations, EC50 and Emax represent the
corresponding estimates for wild-type tissue, y represents
the measured contraction, X represents the concentration of
oxotremorine-M, and n represents the Hill slope. In Eq. 2, δ
represents the change in Emax, and γ represents the scalar
change in EC50 between wild type and M2 KO. For each
treatment (i.e., vehicle or STZ), the concentration–response
curves were fitted simultaneously to Eqs. 1 and 2 sharing
the estimate of Emax and EC50 between wild type and M2
KO and obtaining unique estimates of n for both wild type
and M2 KO and unique estimates of δ and γ for the M2KO.
To test for differences between bladders from vehicle- and
STZ-treated animals, we determined the significance of the
increase in residual variance when the estimate of δ or γ
was shared between the vehicle- and STZ-treated groups as
described by Motulsky and Christopoulos (2003).
We used the operational model (Black and Leff 1983) to
quantify the effect of forskolin on the concentration–
response curve to oxotremorine-M:
y¼

X m Msys
Þ
X m þ ðX þK
tm

m

ð3Þ

In this equation, y represents the measured contraction,
X represents the concentration of oxotremorine-M, Msys
represents the maximum response of the system, K
represents the observed dissociation constant, m represents
the transducer slope factor, and C represents a parameter
related to coupling efficiency. Specifically, the value of C is
proportional to the intrinsic efficacy of the agonist (ε), the
amount of potentially active receptors (RT), and the
sensitivity of the signaling cascade (1/KE). In our experiments, forskolin either caused a shift to the right or both a
shift to the right and a decrease in the Emax of the
concentration–response curve. Both situations were
adequately described by a reduction in the C parameter
of the operational model. The effects of forskolin on the
two disparate parameters, EC50 and Emax, could be
adequately described, therefore, by a decrease in the value
of a single parameter (C ) that accurately accounts for the

inhibitory effect of cAMP on the contractile elements (i.e.,
decrease in 1/KE).
To quantify this effect in bladder from the wild-type
mouse, we analyzed the control concentration–response
curve using Eq. 3 and that measured in the presence of
forskolin using an identical equation, but with the parameter C
replaced with the product, αC :
y¼

X m Msys
þK Þ
X m þ ðXat
m

m

ð4Þ

The parameter α, therefore, represents the factor by
which forskolin reduces the sensitivity of the signaling
pathway for contraction.
To investigate how the M2 receptor opposes forskolininduced relaxation, we compared the relaxant effect of
forskolin in urinary bladder from wild-type and M2 KO
mice. The control concentration–response curve in the M2
KO mouse was analyzed using Eq. 3 and that in the
presence of forskolin was analyzed using an identical
equation, but with the parameter C replaced with the
product, αβC :
y¼

X m Msys
þK Þ
X m þ ðXabt
m

m

ð5Þ

Here, β represents the relative difference, expressed as a
factor, between the effect of forskolin in wild-type (α) and
M2 KO mice (αβ). This parameter, therefore, is a measure
of the role of the M2 receptor in opposing forskolin-induced
relaxation—the smaller the value of β (or alternatively, the
larger the value of −log β), the greater the role of the M2
receptor.
To estimate β, the concentration–response curves in the
absence (control) and presence of forskolin and in both
wild-type and M2 KO mice were fitted simultaneously to
Eqs. 3, 4, and 5 to obtain unique estimates of Msys, m, α,
and β (global nonlinear regression analysis). The estimate
of C was shared among the curves and that of K was shared
between those of control and forskolin conditions. Figure 2
shows a pictorial representation of our analysis, and the
legend describes additional details.
The statistical significance of differences between
parameter estimates measured in urinary bladders from
vehicle- and STZ-treated mice was determined as described
above in connection with Eqs. 1 and 2.

Results
Effects of STZ on body weight and blood glucose
Wild-type and M2 KO mice injected with a single dose
(125 mg kg−1) of STZ exhibited significantly higher fasting
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Fig.

2 Determination of the role of the M2 receptor in opposing
forskolin-induced relaxation. a The plot shows a simulation of a
concentration–response curve to a muscarinic agonist in the absence
(control) and presence of forskolin. The operational model (Eq. 3) was
used to simulate the data. All of the parameters were the same for the
two curves except that the parameter τ for the curve measured in the
presence of forskolin was reduced to one tenth that of the control
curve. The values of the parameters in the simulation were Msys =100,
m=1.65, K=106, and τ=15. b The simulation illustrates the effect of
forskolin on the concentration–response curve to a muscarinic agonist
in smooth muscle from wild-type and M2 KO animals. For the wildtype curves, the effect of forskolin has been simulated by reducing the
value of τ by the factor α. In other words, Eqs. 3 and 4 were used to
simulate the control and forskolin conditions, respectively, with the
value of α set to 0.48 in Eq. 4 and the values of all of the other
parameters the same for the two equations. For the M2 KO curves, the
effect of forskolin has been simulated by reducing τ by the factor αβ,
with α=0.48 as in wild type and β=0.16. It follows that the log
difference in the effect of forskolin in wild type (log α) and M2 KO
(log αβ) is equivalent to log β. The values of the parameters for the
simulations were, wild-type control, Msys =100, m=1.65, K=106, and
τ=18; wild-type forskolin, same as control with α=0.48; M2 KO
control, same as wild type but with log τ=15; M2 KO forskolin, same
as M2 KO but with αβ=0.078. c The plot shows that the role of the
M2 receptor in opposing forskolin-induced relaxation (log β) is
equivalent to the difference between the relaxant effect of forskolin
in wild type (log α) and M2 KO (log αβ). The values of α and β are
the same as those used in the simulation in (b)

blood glucose levels compared to control animals (Table 1).
Body weight decreased significantly more in STZ-treated
mice compared to those treated with vehicle with the
exception of wild-type mice at the 2- to 3-week time point
(Table 1). Although STZ significantly decreased the weight
of M2 KO compared to wild-type mice at 8 to 9 weeks
(Table 1), denuded bladder tissue from these animals did
not exhibit a difference in KCl-induced contraction (data
not shown).
Effects of STZ on denuded urinary bladder
Muscarinic agonist-induced contractions Two to 3 weeks
after treatment with STZ, wild-type urinary bladder lacking
urothelium (denuded) displayed a slight decrease in
contractile responsiveness to oxotremorine-M as compared
to tissue from vehicle-treated mice (Fig. 3a). At both the
8–9- and 20–24-week time points after STZ treatment,
however, the Emax values of oxotremorine-M in denuded

bladders were markedly greater than those from vehicletreated animals (Fig. 3d, g). These effects were manifest
mainly as significant 58% and 61% increases in Emax
when expressed in units of force (millinewton; Table 2).
These data illustrate a time-dependent increase of contractile response in tissues from STZ-treated mice.
When normalized relative to the contraction elicited
by KCl (50 mM), however, the concentration–response
curves in bladder from wild-type mice showed little
difference between vehicle and STZ groups at all time
points (Fig. 3b, e, h and Table 2), suggesting that STZ
treatment might cause smooth muscle hypertrophy or a
general increase in contractility over time. In experiments
on urinary bladder from M2 KO mice, there was little
difference between vehicle and STZ groups at the early
(2–3 weeks) and late (20–24 weeks) time points (Fig. 3c, i).
At the intermediate time point (8–9 weeks), STZ treatment
caused a significant loss of contractile function (Fig. 3f),
which was manifest as a significant 2.3-fold increase in EC50
(Table 2).
To quantify the role of the M2 receptor, we compared the
loss of contractile function in the M2 KO mouse relative to
wild type. In vehicle-treated mice, there was little difference
in the contractile activity of oxotremorine-M in urinary
bladder from wild-type and M2 KO mice. Similarly, there
was little difference in contractile activity between wildtype and M2 KO mice at the early (2–3 weeks) and late
(20–24 weeks) time points after STZ treatment. At the
intermediate time point (8–9 weeks), however, STZ
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Table 1 Body weight percent change and fasting blood glucose levels 2–24 weeks after injection

2–3 weeks after treatment
8–9 weeks after treatment
20–24 weeks after treatment

Percent body weight change

Fasting blood glucose (mgdL−1)

Wild type

Wild type

M2 KO

111.1±14.7 (7)
298.3±59.2 (3)a
115.0±11.2 (6)
431.3±61.3 (6)c
133.0±5.3 (5)

113.7±18.5 (3)
436.0±39.7 (3)a
140.8±8.9 (4)
470.6±37.9 (5)c
127.5±6.3 (4)

458.7±113.3 (3)a

513.7±36.3 (4)c

M2 KO

Vehicle
STZ
Vehicle
STZ
Vehicle

5.9±2.7
1.4±8.5
27.0±2.4
14.3±2.4
48.2±6.7

(7)
(3)
(6)
(6)a
(5)

STZ

14.4±8.3 (3)a

1.2±1.2
−9.2±1.0
21.1±3.5
4.36±1.4
41.2±1.8

(3)
(3)a
(4)
(5)a,
(4)

8.9±4.2 (4)c

b

Vehicle (sodium citrate-buffered saline) and streptozotocin (STZ) were injected intraperitoneally (125 mg kg−1 ). Data are means ± SE (number of
animals)
a

Statistically significant difference from vehicle (P<0.05)

b

Significantly different from STZ-treated wild-type mice (P=0.011)

c

Statistically significant difference from vehicle (P<0.001)

Fig. 3 Effect of streptozotocin (STZ) treatment on oxotremorine-Mmediated contractions in urinary bladder lacking urothelium from
wild-type and M2 KO mice. Concentration–response curves were
measured 2 to 3 weeks (a–c), 8 to 9 weeks (d–f), and 20 to 24 weeks
(g–i) after STZ treatment in urinary bladder from wild-type (a, b, d, e,

g, h) and M2 KO (c, f, i) mice. Contractions are expressed in units of
force (millinewton; a, d, g) or relative to the contraction elicited by
KCl (50 mM; b, c, e, f, h, i). Circles denote the vehicle-treated group;
triangles denote the STZ-treated group. Mean ± SEM values from
three to seven experiments are shown, each done on a separate bladder

M2 muscarinic receptor-mediated inhibition of forskolininduced relaxation We investigated the effect of prior
treatment with STZ on forskolin-induced inhibition of
contraction to oxotremorine-M in denuded urinary bladder
from wild-type and M2 KO mice. Forskolin (5 µM) had a
small inhibitory effect on the concentration–response curve
to oxotremorine-M in wild-type bladder from vehicle- and
STZ-treated mice at all time points (Fig. 4). A much greater
effect was observed in denuded bladder from M 2 KO
mice, which is consistent with the role of the M2
receptor in opposing adenylate cyclase-mediated inhibition of contraction.
We used the operational model (see “Methods” section)
to estimate the relaxant effect of forskolin in urinary
bladder from wild-type (−log α) and M2 KO (−log αβ)
mice. The difference between these two estimates (−log β)
is a measure of the function of the M2 receptor in opposing
forskolin-induced relaxation. The −log β values were
estimated in urinary bladder from vehicle- and STZtreated mice at the three time points, and the results are
summarized in Fig. 5a. At the 8–9- and 20–24-week time
points, STZ treatment caused a significant increase in the
role of the M2 receptor in opposing the relaxant effect of
forskolin.

6.66±0.14
6.53±0.051
6.72±0.071
6.40±0.027
215.60±26.79
168.30±6.51
181.70±12.84
175.30±3.08
6.83±0.052
6.86±0.088
6.73±0.052
6.49±0.11a

Significantly different from wild-type vehicle (P<0.001)

Effects of STZ on intact urinary bladder

b

Data are means ± SE (number of animals)

a

STZ

Statistically significant difference from M2 KO vehicle (P<0.01)

242.20±8.82
249.50±15.35
242.60±8.93
208.60±17.21
48.17±3.76
–
76.28±4.94b
–
6.81±0.14
6.39±0.13
6.73±0.064
6.69±0.087
268.10±30.43
272.60±26.26
259.70±11.89
238.50±14.90
71.38±6.87
–
63.12±6.05
–
WT
M2 KO
WT
M2 KO
Vehicle
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induced a greater loss of function in urinary bladder from
the M2 KO mouse (Fig. 3f) compared to that from wild type
(Fig. 3e), which was manifest as a 3.1-fold increase in EC50
(log shift in EC50 =0.49±0.055; F=21.30, P<0.001). Since
muscarinic contractile function is absent in urinary bladder
from M2/M3 double KO mice (Matsui et al. 2002), these
data indicate that STZ treatment inhibits M3 receptormediated contraction and that this response is restored by
the M2 receptor.

70.27±6.15
–
113.30±7.12b
–

pEC50
Emax (% KCl)
Emax (mN)
Emax (mN)
pEC50
Emax (mN)

Emax (% KCl)

8–9 weeks
2–3 weeks
Denuded bladder

Table 2 Emax and pEC50 values measured in denuded bladders from mice 2–24 weeks after injection

Emax (% KCl)

pEC50

20–24 weeks
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Muscarinic agonist-induced contractions The presence of
urothelium caused a modest change in the contractile
activity of oxotremorine-M in the urinary bladder (Fig. 6).
The overall average Emax value of oxotremorine-M in
intact, wild-type urinary bladder from all of the vehicletreated groups (201.9±8.9%, KCl-normalized contraction,
Fig. 6b, e, h) was significantly smaller than the
corresponding estimate for denuded urinary bladder
(243.4±11.6%, KCl-normalized contraction, Fig. 3b, e, h;
F=8.82; P=0.0033). There was little or no difference in the
contractile activity of oxotremorine-M in denuded bladder
from vehicle-treated wild-type and M2 KO mice at all time
points (Fig. 3). In contrast, the overall average EC50 value
of oxotremorine-M in intact, M2 KO urinary bladder from
all of the vehicle-treated groups (pEC50 =6.38±0.13) was
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Fig. 4 Effect of streptozotocin
(STZ) treatment on M2 receptormediated inhibition of relaxation
in urinary bladder lacking
urothelium. The effect of
forskolin (5 µM) on
oxotremorine-M-mediated
contractile responses was
measured in wild-type and M2
KO bladders 2 to 3 weeks (a, b),
8 to 9 weeks (c–d), and 20 to
24 weeks (e–f) after STZ treatment. Open circles denote wild
type, control; closed circles
denote wild type in the presence
of forskolin; open triangles
denote M2 KO, control; closed
triangles denote M2 KO in the
presence of forskolin. Mean ±
SEM values from three to seven
experiments are indicated, each
done on a separate bladder

significantly greater (lower potency) than the corresponding
estimate for wild-type bladder (pEC50 =6.84±0.055; Fig. 6;
F= 16.029, P<0.001).
Eight to 9 weeks after STZ treatment, the Emax value of
oxotremorine-M, expressed in millinewton, was significantly
greater by 51% in intact urinary bladder from STZ-treated
wild-type mice compared to intact bladder from vehicletreated wild-type animals (Fig. 6d and Table 3). When
contraction was normalized relative to that elicited by KCl
(50 mM; Fig. 6e), this difference persisted (Table 3). STZ
treatment (8 to 9 weeks prior) had no effect on the contractile
action of oxotremorine-M in intact urinary bladder from the
M2 KO mouse (Fig. 6f). Nonetheless, when the activity of
oxotremorine-M in the intact M2 KO bladder is compared to
that of wild type, there is a greater reduction in Emax
following STZ treatment (F=5.11, P=0.026).
These changes were not significant 2 to 3 weeks
(Fig. 6a–c) or 20 to 24 weeks (Fig. 6g–i) after STZ
treatment.

Fig. 5 Effect of streptozotocin treatment on the role of the M2
receptor in opposing forskolin-induced relaxation in denuded (a) and
intact (b) urinary bladder. The function of the M2 receptor is
quantified as the parameter −log β, which is defined as the difference
between the effect of forskolin in urinary bladders from wild-type
(−log α) and M2 KO (−log αβ) mice as described under “Methods”
section. The parameters were estimated from the data in Figs. 4 and 7.
*Significantly different from vehicle, P<0.05

M2 muscarinic receptor-mediated inhibition of forskolininduced relaxation We also investigated M2 receptormediated inhibition of relaxation in urinary bladder with
intact urothelium (Fig. 7). As observed in denuded bladder,
the relaxant effect of forskolin on oxotremorine-M-induced
contractions was greater in intact urinary bladder from the
M2 KO mouse compared to that from wild type, illustrating
the role of the M2 receptor in opposing the relaxant effect
of forskolin. This action of the M2 receptor was significantly enhanced 2 to 3 weeks and 20 to 24 weeks after STZ
treatment (Fig. 5b).
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Fig. 6 Effect of streptozotocin (STZ) treatment on oxotremorine-Mmediated contractions in urinary bladder with intact urothelium from
wild-type and M2 KO mice. Concentration–response curves were
measured 2 to 3 weeks (a–c), 8 to 9 weeks (d–f), and 20 to 24 weeks
(g–i) after STZ treatment in urinary bladder from wild-type (a, b, d, e,

g, h) and M2 KO (c, f, i) mice. Contractions are expressed in units of
force (millinewton; a, d, g) or relative to the contraction elicited by
KCl (50 mM; b, c, e, f, h, i). Circles denote the vehicle-treated group;
triangles denote the STZ-treated group. Mean ± SEM values from
three to seven experiments are shown, each done on a separate bladder

Discussion and conclusions

nonspecific and acute cytotoxicity. Also, it is unlikely that
our mice suffered from diabetic ketoacidosis as urinalysis
test strips showed zero, or very rarely, trace (5 mg dL−1)
amounts of acetoacetic acid in animals treated with STZ at
all time points (data not shown). We found that M3 KO mice
were very sensitive to STZ, and none survived long enough
for experiments. M3 KO mice of a C57BL/6 genetic
background exhibit impaired glucose tolerance (Gautam et
al. 2006), which may contribute to their high sensitivity to
STZ.
We observed that STZ inhibits M2 KO but not wildtype bladder contraction 8 to 9 weeks after treatment
(Fig. 3e, f), suggesting that the M2 receptor rescues
impaired M3 receptor-mediated contraction in denuded
diabetic bladder. Mimata et al. (1995) observed a 30%
increase in carbachol-stimulated phosphoinositide hydro-

In our study, we used a single injection of STZ (125 mg kg−1)
to induce diabetes. This dose was determined to yield
maximal levels of hyperglycemia with minimal mortality
(data not shown). High doses of STZ (≥200 mg kg−1)
promote nonspecific cytotoxicity and acute renal tubular
damage (Tay et al. 2005). When moderate doses (100–
125 mg kg−1) are used on two consecutive days, nonspecific
and acute renal cytotoxicity is markedly reduced, and mice
develop renal injury biochemically and histologically similar
(albeit less severe) to human nephropathy (Tesch and
Nikolic-Paterson 2006; Tesch and Allen 2007), which can
develop as a late diabetic complication after 10–20 years
(Molitch et al. 2004). Our use of a single injection of STZ
(125 mg kg−1) probably caused even less STZ-induced

201.20±26.81
168.80±15.63
161.40±21.21
157.90±11.02
68.64±10.40
–
71.21±6.17
–
6.90±0.080
6.63±0.11
6.91±0.10
6.70±0.10
197.20±10.90
227.20±18.14
248.60±16.69a
199.40±14.93
35.53±3.96
–
53.63±6.14a
–

a

Data are means ± SE (number of animals)

STZ

Statistically significant difference from wild-type vehicle (P<0.01)

6.87±0.099
6.44±0.22
6.69±0.16
6.80±0.14
218.50±18.04
242.20±40.89
269.70±31.94
212.30±19.14
51.50±4.28
–
54.48±8.48
–
WT
M2 KO
WT
M2 KO
Vehicle

Emax (% KCl)
Emax (mN)
Emax (mN)
Emax (% KCl)

pEC50
Emax (mN)

Emax (% KCl)

pEC50

20–24 weeks
8–9 weeks
2–3 weeks
Intact bladder

Table 3 Emax and pEC50 values measured in intact bladders from mice 2–24 weeks after injection

6.62±0.14
6.47±0.096
6.69±0.14
6.36±0.091
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lysis in [3H]inositol-labeled diabetic rat bladder when this
response was expressed as the conversion of labeled [3H]
phosphoinositides into [3H]inositol phosphates. Since the
M 3 receptor is known to mediate phosphoinositide
hydrolysis in mouse urinary bladder (Tran et al. 2006),
the results of Mimata et al. (1995) suggest an increase in
M3 function in diabetic bladder. Perhaps this increase
might contribute to the overall increase in muscarinic
receptor-induced contractile force (millinewton) that we
observed in wild-type mouse urinary bladder. Most of this
increase in contraction can be attributed to the M2
receptor, however, which does not signal through phosphoinositide hydrolysis in mouse urinary bladder (Tran et
al. 2006). Also, the increase in muscarinic contractile
force was absent when contractions were normalized
relative to that elicited by KCl. Alternatively, there may
be differences in the effects of STZ on urinary bladder
from rats and mice.
Previous work from our lab has shown that the M2
receptor enhances contractions elicited by the M3 receptor
in colon (Sawyer and Ehlert 1999) and urinary bladder
(Ehlert et al. 2005) from normal guinea pig and mouse,
respectively. This M2 enhancement mechanism acts at a
lower potency than that required for M3-mediated contractions, and oxotremorine-M elicits a maximal contraction
through the M3 receptor at a concentration that is too low to
activate the M2 enhancement function (Sawyer and Ehlert
1999; Ehlert et al. 2005). When a portion of the population
of M 3 receptors is pharmacologically inactivated,
oxotremorine-M is still able to elicit maximal contraction,
albeit at a 20-fold lower potency. In these bladders,
inhibition of M2 receptor signaling by pertussis toxin
(Sawyer and Ehlert 1999) or by gene deletion (Ehlert et
al. 2005) induces a substantial loss of function in urinary
bladder, revealing M2 enhancement of contractions elicited
by the M3 receptor. Since the M3 receptor can elicit a
maximal contraction on its own, the normal physiological
significance for the M2 enhancement mechanism is unclear,
but the observation in the current study that this mechanism
rescues M3 receptor-mediated contractions, which have
been attenuated by STZ treatment, may suggest that the M2
receptor has a crucial role in sustaining function in disease
states such as diabetes.
A similar upregulation in M2 receptor function occurs
with denervation of the urinary bladder or obstruction of its
outlet. In the rat model of these conditions, there is an
upregulation of M2 muscarinic receptor expression and
mRNA, an increase in the potency of muscarinic agonists
for eliciting contraction, and a change in the potency of
antagonists for inhibiting contraction that is consistent with
a greater role for the M2 receptor (Braverman et al. 1998,
1999). This increase in M2 function is caused by hypertrophy of the bladder because the increase in M2 receptor
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Fig. 7 Effect of streptozotocin
(STZ)-treatment on M2 receptormediated inhibition of relaxation
in urinary bladder with intact
urothelium. The effect of
forskolin (5 µM) on
oxotremorine-M-mediated
contractile responses was
measured in wild-type and M2
KO bladders 2 to 3 weeks (a, b),
8 to 9 weeks (c, d), and 20 to
24 weeks (e, f) after STZ treatment. Open circles denote wild
type, control; closed circles
denote wild type in the presence
of forskolin; open triangles
denote M2 KO, control; closed
triangles denote M2 KO in the
presence of forskolin. Mean ±
SEM values from three to seven
experiments are indicated, each
done on a separate bladder

expression is prevented in rats that have had their ureters
sutured to the colon to divert the flow of urine to the GI
tract and prevent the denervation-induced distension and
hypertrophy of the bladder (Braverman and Ruggieri
2003). An analogous increase in M2 function has been
observed in human urinary bladder with reduced innervation as a result of spinal injury (Pontari et al. 2004;
Ruggieri and Braverman 2006).
Another role of the M2 receptor involves inhibition of
cAMP-mediated relaxation in smooth muscle from mouse
(Matsui et al. 2003; Ehlert et al. 2005, 2007), guinea pig
(Noronha-Blob et al. 1989; Thomas et al. 1993), and rat
(Hegde et al. 1997). In the current study, we investigated
how STZ treatment affects this M2 receptor-mediated
disinhibition of contraction by comparing the degree of
forskolin-induced inhibition of muscarinic contractions in
M2 KO versus wild-type bladders. Forskolin had a greater
effect on the concentration–response curve to oxotremorineM (i.e., rightward shift) in bladder from M2 KO mice
compared to that from wild-type animals, illustrating the
ability of the M2 receptor to oppose the relaxant effect of
forskolin. This M2 disinhibition of contraction was
significantly greater at the intermediate (8–9 weeks) and
long (20–24 weeks) time points after STZ treatment in
denuded urinary bladders (Fig. 5a). These data are
consistent with the observation that STZ treatment
increases M2 receptor expression (Tong et al. 1999,
2002a, b, 2006; Stevens et al. 2006) in bladder smooth
muscle.
Urothelium is known to release an inhibitory factor upon
muscarinic stimulation (Hawthorn et al. 2000; Kosan et al.

2005). Our results are consistent with this phenomenon,
because we found that oxotremorine-M exhibited a significantly greater Emax value for contraction in denuded wild
type compared to intact wild type urinary bladder. We also
found that while there was no difference in the contractile
activity of oxotremorine-M in denuded bladder from wildtype and M2 KO mice, the agonist did exhibit 2.9-fold
lower potency in intact M2 KO relative to intact wild-type
urinary bladder. Previously, we reported a similar difference
in intact bladder (Matsui et al. 2003). These results might
suggest that urothelial M2 receptors mediate an inhibition of
the release of the inhibitory factor, whose initial release is
stimulated by a muscarinic subtype other than M2. The
human urothelium expresses mRNA for all muscarinic
subtypes, with M2 mRNA greatly exceeding that of the
other subtypes (Bschleipfer et al. 2007). Urothelial M2
(Tong et al. 2006) and M3 (Cheng et al. 2007) receptor
expression is upregulated with STZ treatment. The urothelium is now known to be more involved in bladder function
beyond its traditional role as a passive barrier to underlying
smooth muscle (Birder and de Groat 2007).
The inhibitory effect of the urothelium on muscarinic
contractility is abolished by STZ treatment in rats, suggesting
a loss in release of the inhibitory factor (Kosan et al. 2005).
We also confirmed that STZ treatment enhanced contractions
in intact wild-type mouse urinary bladder (Fig. 6e), but had
no effect on denuded wild-type bladder when contraction
was normalized relative to KCl (Fig. 3e).
In denuded M2 KO bladder (Fig. 3f), we found that STZ
treatment inhibited muscarinic contractile potency, whereas in
intact M2 KO bladder (Fig. 6f), STZ treatment had no effect.
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This seemingly conflicting result can be explained by the
opposing effects of STZ treatment on muscarinic contractility
in intact M2 KO urinary bladder—an enhancement from the
loss of urothelial inhibition and an inhibition from a loss of
M3 function. The loss of M3 function was manifest in intact
urinary bladder as a significant reduction in the Emax of
oxotremorine-M in M2 KO relative to wild type 8 to 9 weeks
after STZ treatment. This loss of function was significantly
greater than that observed in intact bladder from vehicletreated animals. Thus, our hypothesis that STZ treatment
inhibits M3 receptor contractile function in smooth muscle
and that the smooth muscle M2 receptor rescues contractile
function is supported by our findings on both denuded and
intact bladder 8 to 9 weeks after STZ treatment. This effect
seems to be short-lived, however, because it is lost 20 to
24 weeks after STZ treatment.
Our experiments on the role of the M2 receptor in
opposing forskolin-induced relaxation in intact bladders
showed an increase in this function following STZ
treatment. We observed a significant increase in M2
function at the early (2–3 weeks) and late (20–24 weeks)
time points after STZ treatment, but not at the intermediate
time point (8–9 weeks). In denuded bladder, significant
differences were measured at the intermediate and late time
points. We have no explanation for this difference, but
experimental variation and changes in the effect of forskolin
on the release of mediators from the urothelium after STZ
treatment (Birder et al. 2002) may confound our results.
This temporal progression of differential changes in M2
and M3 contractile function in urinary bladder is likely
caused by gradual STZ-induced alterations. Hyperglycemiainduced neuronal dysfunction and subsequent damage to the
neuromuscular junction may alter contractile function in
smooth muscle. Additionally, the rich innervation of the
urothelium (Wakabayashi et al. 1995) and its high level of
glucose metabolism may make urothelial tissue gradually
susceptible to diabetic conditions. Our results provide a
clearer understanding of the differential roles of M2 and M3
muscarinic receptors in STZ-induced diabetes and how the
M2 receptor maintains contractile function in this disease
model.
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